Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Gemcitabine in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors

Trial Profile

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Gemcitabine in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2016

At a glance

  • Drugs Lurbinectedin (Primary) ; Gemcitabine
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors PharmaMar
  • Most Recent Events

    • 12 Nov 2016 Results published in the Investigational New Drugs
    • 05 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top